ClinicalTrials.gg
TerminatedNCT02791256Updated Jun 8, 2016

A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6

A Phase 3 interventional study of Ribavirin and peginterferon alfa-2a in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Terminated at 21 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-08.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 175 studies testing ribavirin in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Ribavirin · Hepatitis C, Chronic.

Enrollment
153rd of 174
23 · median 107
Started
2005
with 16 others
Phase 3
61 of 175
none open now
Registered
165th of 175
by date
Lead sponsor
28 of 175
Hoffmann-La Roche

Among the 175 studies testing ribavirin in Hepatitis C, Chronic, this one is the 153rd largest by enrollment of the 174 interventional ones that give a count, is one of 17 that started in 2005, is one of 61 in phase 3, and was the 165th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 175 studies testing ribavirin in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 175 studies testing ribavirin in Hepatitis C, Chronic as a file.
02

Study summary

This multicenter, open-label, uncontrolled study will evaluate the efficacy and safety of increasing the dose of peginterferon alfa-2a (Pegasys) in participants with Genotype 1/4/5/6 CHC and an early non-response to a standard course of peginterferon alfa-2a plus ribavirin. The study will consist of screening (4 weeks), treatment (32 weeks), and follow-up (24 weeks).

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with serologic evidence of chronic infection by an anti-HCV antibody test
  • Participants had to have been receiving their first treatment for chronic hepatitis C (i.e. previously naive to any therapy) consisting of peginterferon alfa-2a plus ribavirin for 16 weeks (+/- 10 days), without reaching a negative or 2-log drop of Serum Hepatitis C Virus Ribonucleic Acid (HCV-RNA) at Week 12 of therapy as compared to pretreatment value, and must still be on therapy (no wash out)
  • HCV-RNA quantifiable by a test reporting in international units
  • Compensated liver disease ( Grade A clinical classification)
  • Participants with cirrhosis or transition to cirrhosis had to have an abdominal ultrasound, computerized tomography (CT) scan, or magnetic resonance imaging (MRI) scan without evidence of hepatocellular carcinoma and a serum alpha fetoprotein (AFP) less than (\<)100 nanogram pe milliliter (ng/mL) within 6 months of study entry
  • Negative urine or blood pregnancy test
  • Participants had to be using two forms of effective during treatment and during the 6 months after treatment end
  • Able to participate and to comply with the study restrictions

Exclusion criteria

Exclusion Criteria:

  • Women with ongoing pregnancy or who are breast feeding and male partners of women who were pregnant
  • \<1,500 cells/cubic millimeter (mm\^3) or count \<90,000 cells/mm\^3 before initiation of the ongoing treatment regimen; or neutrophil count \<750 cells/mm\^3 or platelet count \<50,000 cells/mm\^3 at screening while still on therapy with peginterferon alfa-2a plus ribavirin
  • (Hgb) \<12 gram per deciliter (g/dL) before initiation of the ongoing treatment regimen; or Hgb \<10 g/dL at screening while still on therapy with peginterferon alfa-2a plus ribavirin for at least 12 weeks
  • Serum creatinine level greater than (>)1.5 times the at screening
  • Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of and radiation) other than the currently failing Pegasys plus ribavirin combination therapy less than or equal to (\<=) 6 months prior to the first dose of study drug
  • Positive test for hepatitis A immunoglobulin M (IgM) antibody (anti-HAV IgM Ab), surface antigen (HBsAg), anti-hepatitis B core IgM antibody (anti-HBc IgM Ab), anti- antibody (anti-HIV Ab)
  • History or other evidence of a medical condition associated with chronic liver disease other than
  • History of bleeding from esophageal varices or other conditions consistent with decompensated liver disease, severe psychiatric disease (especially depression), severe seizure disorder, thyroid disease, immunologically mediated disease, chronic pulmonary disease, cardiac disease, major organ transplantation or other evidence of severe illness,
  • Evidence of drug abuse including excessive alcohol consumption
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Peginterferon Alfa-2a + Ribavirin

    Participants will receive 360 microgram (mcg) of Peginterferon Alfa-2a subcutaneous (SC) once a week plus ribavirin (1000 - 1200 milligram per day \[mg/day\] orally as a split dose in the morning and the evening based on the participant's body weight) for 32 weeks.

    Drug: Ribavirin · Drug: peginterferon alfa-2a

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Virologic Response, as measured by ultrasensitive Roche HCV TaqMan Test

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving Sustained Virologic Response (SVR), as measured by ultrasensitive Roche HCV TaqMan Test

    Time frame: Week 56

  2. Percentage of Participants Achieving End-of-treatment Response, as measured by ultrasensitive Roche HCV TaqMan Test

    Time frame: Week 32

  3. Mean Log Change From Baseline to Week 2, 4, 8, 12, 32, and 56 in Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Viral Load

    Time frame: Baseline, Week 2, 4, 8, 12, 32, 56

  4. Number of Participants With Adverse Events and Serious Adverse

    Time frame: Baseline up to Week 56

07

Study locations

21 sites
  • Antwerp, 2018, Belgium
  • Antwerp, 2060, Belgium
  • Bruges, 8000, Belgium
  • Brussels, 1000, Belgium
  • Brussels, 1020, Belgium
  • Brussels, 1070, Belgium
  • Brussels, 1090, Belgium
  • Brussels, 1180, Belgium
  • Brussels, 1190, Belgium
  • Brussels, 1200, Belgium
  • Charleroi, 6000, Belgium
  • Edegem, 2650, Belgium
  • Ghent, 9000, Belgium
  • Gilly, 6060, Belgium
  • Haine-Saint-Paul, 7100, Belgium
  • Kortrijk, 8500, Belgium
  • Leuven, 3000, Belgium
  • Liège, 4000, Belgium
  • Namur, 5000, Belgium
  • Roeselare, 8800, Belgium
  • Yvoir, 5530, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2016
First posted
Jun 6, 2016
Start
Jun 2005
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Last update
Jun 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02791256
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 6, 2016
Start date
Jun 2005
Primary completion
Jun 2008
Completion
Jun 2008
Last update
Jun 8, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ribavirin · Peginterferon alfa-2a

Start the discussion